Pharmaceutical and Medical Devices Agency (PMDA), Japan has completed Good Manufacturing Practices (GMP) inspection at Lupin’s Goa facility (Unit - I & II). The inspection was conducted between September 24, 2019 and September 27, 2019. The PMDA inspection closed with no critical or major observations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.